1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in the United States, January 2019 (p5)

Healthcare Analysis & Statistics in the United States, January 2019 (p5)

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence

All regions

data types

121-150 of about 300 reports

Ischemic Stroke Market and Forecast Analysis 2024

Ischemic Stroke Market and Forecast Analysis 2024

  • $ 22000
  • Industry report
  • January 2019

Disease OverviewStroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to ...

  • Industries : Therapy, Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Chronic Heart Failure Market and Forecast Analysis to 2024, Pharma Intelligence

Chronic Heart Failure Market and Forecast Analysis to 2024, Pharma Intelligence

  • $ 22000
  • Industry report
  • January 2019

Disease OverviewChronic heart failure (CHF) is a serious medical condition in which the heart is unable to adequately fill with and eject blood. CHF can result from functional abnormalities such as ventricula ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, European Union, Japan
2018 ASH Pulse Survey

2018 ASH Pulse Survey

  • $ 599
  • Industry report
  • January 2019

OverviewThis 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe asks respondents their thoughts on several topics presented at the 2018 American Society ...

  • Industries : Cancer, Pathology
  • Countries : United States
Osteoporosis Market and Forecast Analysis, Pharma Intelligence

Osteoporosis Market and Forecast Analysis, Pharma Intelligence

  • $ 22000
  • Industry report
  • January 2019

DISEASE OVERVIEWOsteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue. The consequent increase in ...

  • Industries : Chronic Disease, Pathology, Therapy
  • Countries : United States, Japan, European Union
Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices

Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices

  • $ 4750
  • Industry report
  • December 2018

OverviewMarkets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. This ...

  • Industries : Cardiovascular Devices
  • Countries : World, United States, Japan
Pneumovax 23

Pneumovax 23

  • $ 10000
  • Industry report
  • December 2018

Drug OverviewPneumovax 23 is a 23-valent polysaccharide vaccine containing 23 purified capsular antigens of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, ...

  • Industries : Therapy
  • Countries : United States
Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US

  • $ 599
  • Industry report
  • November 2018

OverviewAn interview with a US key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential fo ...

  • Industries : Therapy
  • Countries : United States
Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US

  • $ 599
  • Industry report
  • November 2018

OverviewAn interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, ...

  • Industries : Therapy
  • Countries : United States
Diabetes Type 1 Market and Forecast Analysis to 2025

Diabetes Type 1 Market and Forecast Analysis to 2025

  • $ 22000
  • Industry report
  • October 2018

DISEASE OVERVIEWDiabetes mellitus is a group of chronic endocrine disorders characterized by hyperglycemia due to insufficient levels of insulin, a hormone responsible for regulating blood sugar. Type ...

  • Industries : Chronic Disease, Pathology, Therapy
  • Countries : Japan, United States, European Union
Diabetes Type 2 Market and Forecast Analysis to 2024

Diabetes Type 2 Market and Forecast Analysis to 2024

  • $ 22000
  • Industry report
  • October 2018

DISEASE OVERVIEWDiabetes occurs when the body cannot use sugars properly due to impaired insulin production or utilization. Prolonged hyperglycemia (high blood sugar) can lead to serious complications ...

  • Industries : Chronic Disease, Pathology
  • Countries : European Union, United States, Japan
Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025

Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025

  • $ 22000
  • Industry report
  • October 2018

Disease OverviewPulmonary arterial hypertension is one of a group of rare and life-threatening diseases collectively known as pulmonary hypertension (PH). Each PH subgroup shares similar pathophysiology, ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, European Union, Japan
Tracleer

Tracleer

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewTracleer (bosentan; Johnson and Johnson) was the first oral therapy to be developed specifically for the treatment of PH. Tracleer is a competitive endothelin receptor type A and B antagonist, ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Revatio

Revatio

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewRevatio (sildenafil; Pfizer) is a selective inhibitor of the PDE5 enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide. The extracellular vasodilator NO activates ...

  • Industries : Chronic Disease
  • Countries : United States, Japan, European Union
esuberaprost

esuberaprost

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewEsuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation ...

  • Industries : Therapy
  • Countries : United States
bardoxolone methyl

bardoxolone methyl

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewBardoxolone methyl (AbbVie/Kyowa Hakko Kirin), under development by the research-stage company Reata Pharmaceuticals, is a Phase III candidate in clinical trials for the treatment of pulmonary ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Uptravi

Uptravi

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewUptravi (selexipag; Johnson and Johnson/Nippon Shinyaku) is a first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist. The drug and its active metabolite, ACT-333679, ...

  • Industries : Chronic Disease
  • Countries : United States, Japan, European Union
Opsumit

Opsumit

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewOriginally developed by Actelion, Johnson and Johnson’s Opsumit (macitentan) is the follow-on product to the leading pulmonary hypertension therapy Tracleer. The drug is a next-generation ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Adempas

Adempas

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewAdempas (riociguat; Bayer/Merck and Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle ...

  • Industries : Drug Development
  • Countries : United States, Japan, European Union
INOpulse

INOpulse

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewINOpulse (Bellerophon Therapeutics) is a drug-device combination being developed to deliver a continuous, pulsed dose of nitric oxide via intranasal inhalation. The INOpulse delivery system ...

  • Industries : Therapy, Chronic Disease, Pathology
  • Countries : United States
Tyvaso

Tyvaso

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewUnited Therapeutics developed Tyvaso (treprostinil) as a follow-on product to Remodulin. As an inhaled formulation of treprostinil, Tyvaso is better tolerated than continuously and subcutaneously ...

  • Industries : Therapy, Chronic Disease, Pharmaceutical
  • Countries : United States
Neuropathic Pain Market and Forecast Analysis to 2026

Neuropathic Pain Market and Forecast Analysis to 2026

  • $ 22000
  • Industry report
  • October 2018

Disease OverviewNeuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

  • $ 2995
  • Industry report
  • October 2018

Spend on breast cancer medicines is a high-level concern for payers, but few access restrictions are in placeDespite a high level of concern regarding spend on breast cancer medicines, access restrictions ...

  • Industries : Cancer
  • Countries : United States, European Union, Japan
Datamonitor Healthcare Type 2 Diabetes KOL Interview – US

Datamonitor Healthcare Type 2 Diabetes KOL Interview – US

  • $ 599
  • Industry report
  • October 2018

OverviewIn this discussion with a US KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients. ...

  • Industries : Therapy
  • Countries : United States
NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034, Pharma Intelligence

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034, Pharma Intelligence

  • $ 22000
  • Industry report
  • October 2018

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Blincyto

Blincyto

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewBlincyto (blinatumomab; Amgen/AstraZeneca/Astellas), produced in Chinese hamster ovary cells, is a bispecific T-cell engager that directs T-cells to target CD19-positive benign and malignant ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Cancer
  • Countries : United States, Japan, European Union
polatuzumab vedotin

polatuzumab vedotin

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewPolatuzumab vedotin (Roche) is an antibody-drug conjugate (ADC) that combines a humanized immunoglobulin (Ig)-G1 monoclonal antibody (MAb) targeting human B-cell surface antigen cluster of ...

  • Industries : Therapy, Medical Biotechnology, Oncology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Kinenza

Kinenza

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewKinenza (enzastaurin) is an oral serine/threonine kinase inhibitor that suppresses signaling of protein kinase C (PKC)-beta to induce cell apoptosis, reduce cell proliferation, and suppress ...

  • Industries : Cancer, Therapy, Pathology, Oncology
  • Countries : United States
Selinexor

Selinexor

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewSelinexor (Karyopharm Therapeutics/Ono Pharmaceutical) selectively inhibits the transport protein exportin-1 (XPO1), also called chromosome region maintenance-1. XPO1 is responsible for the ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, Japan, European Union
Bavencio

Bavencio

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewBavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
MOR208

MOR208

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewMorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Cancer
  • Countries : United States, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on